Ongoing HTA by the Scottish Health Technologies Group in March 2026

The Scottish Health Technologies Group (SHTG) is a national health technology assessment (HTA) body within Healthcare Improvement Scotland. Its primary role is to offer evidence-based advice to NHS Scotland on the use of non-medicine health technologies, such as devices, diagnostics, digital tools, and procedures, to inform safe, cost-effective, and equitable care decisions across Scotland.

SHTG produces three main types of reports: Recommendations, Assessments, and Innovative Medical Technology Overviews (IMTOs).

SHTG Recommendations are comprehensive HTAs developed within 6–9 months by a national committee in consultation with key stakeholders. They consider clinical effectiveness, safety, cost-effectiveness, patient and public perspectives, expert opinions, and potential social or organizational impacts. Where appropriate, SHTG may adapt external HTAs. Health Boards and Integration Authorities in Scotland are required to consider SHTG Recommendations in their decision-making.

As of March 2026, SHTG is developing three new Recommendations on:

• Surface Guided Radiation Therapy;
• Virtual wards;
• Robotic Assisted Bronchoscopy.

SHTG Assessments provide targeted analytical support for health and social care decision-making and are typically completed within 3–6 months. They may include a critical appraisal or summary of existing evidence, and where relevant, primary analyses such as economic modelling or budget impact assessments. Assessments do not include formal recommendations and are issued “for information” only.

As of March 2026, SHTG is developing two new Assessments on:

• Wearable home-testing devices for diagnosing obstructive sleep apnoea syndrome;
• Out-of-hospital cardiac arrest.

SHTG IMTOs are rapid, light-touch overviews of emerging evidence for innovative technologies, developed within 1–2 months. They describe the technology and its innovative aspects, outline potential impacts on health and social care in Scotland, and summarize the strengths and weaknesses of the evidence base. Same as Assessments, IMTOs provide no recommendations and are published “for information” only.

As of March 2026, SHTG is developing three IMTOs on:

• Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome;
• Artificial intelligence (AI) to estimate computed tomography fractional flow reserve (CT-FFR);
• Intelligent Liver Function Testing (iLFT) for the earlier diagnosis of chronic liver disease.

See the full details in English here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.